Concentra Group (CON) has been beaten down lately with too much selling pressure. While the stock has lost 8.5% over the past ...

In a report released today, Ben Hendrix from RBC Capital reiterated a Buy rating on Concentra Group Holdings Parent, Inc. (CON – Research ...

JPMorgan analyst Lisa Gill raised the firm’s price target on Concentra (CON) to $30 from $29 and keeps an Overweight rating on the shares.

Concentra®, the nation’s leader in occupational medicine, today announced the opening of a new medical center in Waukegan, ...

With Concentra Biosciences expanding its stock influence in Pliant Therapeutics and Acelyrin, the two biotechs have shored up ...

Concentra Biosciences offers $3/share + CVR for Acelyrin, outperforming Alumis' bid. Read why I rate SLRN stock a Sell at ...

ADDISON, Texas, March 18, 2025--Concentra®, the nation’s leader in occupational medicine, today announced the opening of a new medical center in Waukegan, Illinois. The medical center ...

Pliant follows in the footsteps of Acelyrin, which also enacted a stockholder rights program on Thursday to protect ...

Acelyrin had been all set to merge into Alumis—but a surprise offe r by Concentra Biosciences has thrown the deal into doubt. As part of an agreement announced two weeks ago, eye-disease-focused ...

On a per-share basis, the Mechanicsburg, Pennsylvania-based company said it had profit of 17 cents. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by ...

Concentra acquired five clinics in Miami-Dade County. The clinics specialize in work injury care and drug testing. OM ...

Concentra Group (CON) has been beaten down lately with too much selling pressure. While the stock has lost 8.5% over the past four weeks, there is light at the end of the tunnel as it is now in ...